Last reviewed · How we verify
NCT02342730
Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia
NA trial testing Weight Loss Specialist in Complex Endometrial Hyperplasia With Atypia in 127 participants. Completed in 18 May 2015.
18 May 2015
Quick facts
| Lead sponsor | Case Comprehensive Cancer Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 127 |
| Start date | 17 December 2014 |
| Primary completion | 18 May 2015 |
| Estimated completion | 18 May 2015 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Weight Loss Specialist
- Quality-of-Life Assessment
- Medical Chart Review
Conditions studied
- Complex Endometrial Hyperplasia With Atypia — all drugs for Complex Endometrial Hyperplasia With Atypia →
- Stage IA Uterine Corpus Cancer — all drugs for Stage IA Uterine Corpus Cancer →
- Stage IB Uterine Corpus Cancer — all drugs for Stage IB Uterine Corpus Cancer →
- Stage II Uterine Corpus Cancer — all drugs for Stage II Uterine Corpus Cancer →
Sponsor
Case Comprehensive Cancer Center — full company profile →
Who can join
Adults 18 to 65, female only, with Complex Endometrial Hyperplasia With Atypia or Stage IA Uterine Corpus Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This pilot clinical trial studies whether obese stage I-II endometrial cancer survivors or patients with atypical hyperplasia (abnormal cells in the lining of the uterus) would go see a weight loss specialist if it was recommended by their cancer doctor. Excess body weight or obesity is one of the most common contributors to (causes of) endometrial cancer. Over two-thirds of women who have survived endometrial cancer are obese. Complications of obesity, such as heart disease are often more dangerous than the cancer itself. A weight loss of even 5-10% of excess body weight is associated with improved health. Often, meeting with a doctor or person who is an expert in weight loss (bariatric specialist) is the best way to lose weight and keep it off. Endometrial cancer survivors or patients with atypical hyperplasia who go see a weight loss specialist recommended by their doctor may be able to achieve a healthier body weight.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Fertility-Sparing Approaches in Atypical Endometrial Hyperplasia and Endometrial Cancer Patients: Current Evidence and Future Directions.
Contreras NA, Sabadell J, Verdaguer P, Julià C, et al · · 2022 · cited 60× · PMID 35269674 · DOI 10.3390/ijms23052531
Verify or expand the search:
- PubMed search for NCT02342730
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Case Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT06811454 — Mindfulness-based Intervention for Depressive Symptoms Sent Via Text (MINDSET) · NA · not yet recruiting
- NCT07167056 — Artificial Intelligence-Powered Support For Quality Of Life Improvement In Participants With Cancer · NA · recruiting
- NCT07084779 — Investigation of Impact of AI on Prostate Cancer Workflow · NA · recruiting
- NCT06904482 — Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood · Phase 2 · recruiting
- NCT07044362 — Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02342730 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Case Comprehensive Cancer Center
- Last refreshed: 19 November 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02342730.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing